Interpretation According to Clone-Specific PD-L1 Cutoffs Reveals Better Concordance in Muscle-Invasive Urothelial Carcinoma
Because immune checkpoint inhibitors have been approved for treating advanced urothelial carcinoma (UC), programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays have been widely used as companion or complementary diagnostic tests for predicting treatment outcomes. Because different clone...
Main Authors: | Tzu-Hao Huang, Wei Cheng, Yeh-Han Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Diagnostics |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4418/11/3/448 |
Similar Items
-
Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients
by: Veronika Weyerer, et al.
Published: (2021-05-01) -
Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
by: Utpal Kumar, et al.
Published: (2022-06-01) -
Status of PD-1 and PD-L1 expression in invasive urothelial carcinoma of the bladder with mismatch repair protein deficiency
by: Nuran Sungu, et al.
Published: (2023-10-01) -
Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma
by: Magdalena Zajac, et al.
Published: (2019-09-01) -
TO WHAT EXTENT EFL LEARNERS HAVE MASTERED CONCORD
by: Amri Isyam
Published: (2009-12-01)